<DOC>
	<DOC>NCT01609049</DOC>
	<brief_summary>This prospective observational study will evaluate the efficacy and safety of Pegasys (peginterferon alfa-2a) in combination with ribavirin in patients with chronic hepatitis C, including patients with compensated liver cirrhosis, in clinical practice. Data will be collected from patients receiving Pegasys and ribavirin during up to 72 weeks of treatment (according to registered indications depending on baseline viral load, genotype and virological response) and a 24-week follow-up.</brief_summary>
	<brief_title>An Observational Study of Pegasys (Peginterferon Alfa-2a) in Combination With Ribavirin in Patients With Chronic Hepatitis C and Compensated Liver Cirrhosis (STANDART)</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adult patients, &gt;/= 18 years of age Serologically confirmed Chronic hepatitis C, HCV RNA detectable Compensated liver cirrhosis (ChildPugh Class A) included Initiating combined therapy with Pegasys and ribavirin HIV coinfection Contraindications for combined therapy according to actual prescribing information</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>